---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-054725"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-05-12T11:30:21+00:00"
generated_at: "2026-05-12T11:38:38.247538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X for Obstructive Sleep Apnea

## Summary
- Awarded 'Best New Technology Solution for Drug Development' in 10th annual MedTech Breakthrough Awards program.
- IHL-42X is a fixed-dose combination of dronabinol and acetazolamide targeting key drivers of OSA.
- Phase 2 RePOSA trial showed statistically significant reductions in AHI and improvements in oxygenation, sleep quality, and fatigue.
- CEO Joel Latham noted the award validates progress and potential to redefine OSA treatment paradigm.
- Recognition comes as Incannex advances IHL-42X toward late-stage development and explores strategic opportunities.

## SEC filing metadata
- accession: 0001213900-26-054725
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-05-12T11:30:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026054725/0001213900-26-054725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026054725/ea0289813-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-054725
- JSON: https://secwatch.observer/filing/0001213900-26-054725.json
- Plain text: https://secwatch.observer/filing/0001213900-26-054725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.